In 2018, systemic adjuvant therapies with immune check point inhibitors (ICI): nivolumab and pembrolizumab and targeted BRAF/MEK inhibitors (BRAF/MEKi): dabrafenib plus trametinib were officially introduced in Europe based on the positive results of randomized phase III clinical trials: Checkmate-238 (for nivolumab vs. ipilimumab), Keynote-054 (for pembrolizumab vs. placebo), and Combi-AD (for dabrafenib plus trametinib vs. placebo) [8,9,10]. Here, BRAF is linked to Alzheimer disease.